Menu Search
Equities

Bristol-Myers Squibb Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BRM:STU

Bristol-Myers Squibb Co

Actions
  • Price (EUR)40.76
  • Today's Change-0.985 / -2.36%
  • Shares traded471.00
  • 1 Year change+1.85%
  • Beta0.3774
Data delayed at least 15 minutes, as of Jul 18 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

  • Revenue in USD (TTM)47.64bn
  • Net income in USD5.42bn
  • Incorporated1933
  • Employees34.10k
  • Location
    Bristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
  • Phone+1 (609) 252-4621
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BMY:NYQ since
announced		Transaction
value
2Seventy Bio IncDeal completed10 Mar 202510 Mar 2025Deal completed-22.48%238.66m
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.